2025-10-20 10:35
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2026
The 2025 Annual General Meeting resolved that the Chairman of the Board shall convene the three largest shareholders in the company in terms of voting...
Communication with the FDA continues, and IBT is focused on obtaining drug approval for IBP-9414 in the US as soon as possible. The next step is a Pre-BLA...
2025-09-10 09:38
IBT presented “Avoiding the severe consequences of NEC” at the NEC Society Symposium in Chicago
Infant Bacterial Therapeutics AB (IBT) presented clinical outcomes following the administration of IBP-9414, an investigational Live Biotherapeutic Product...
Message from CEO IBT continues preparations for the launch of IBP-9414, a drug that can prevent the serious medical consequences of NEC in premature infants...
2025-05-14 07:30
Infant Bacterial Therapeutics (IBT) to present results of “The Connection Study” at ESPGHAN 2025 in Helsinki
Infant Bacterial Therapeutics (IBT) is pleased to announce that results from its pivotal Phase III trial, The Connection Study, will be presented at the...
2025-05-08 17:45
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2025, among other things, the following was resolved: ContactsStaffan...
In accordance with the agreement reached with the FDA on 19 December 2024, IBT has today submitted the Clinical Study Report (CSR) for ‘The Connection...
Message from CEO The US Food and Drug Administration (FDA) has granted IBP-9414 “Breakthrough Therapy Designation.” This means that the FDA...
2025-04-24 07:20
Infant Bacterial Therapeutics (IBT) to Present Results of “The Connection Study” at PAS 2025 in Honolulu
Infant Bacterial Therapeutics (IBT) is pleased to announce that results from its pivotal Phase III trial, “The Connection Study,” will be presented...
2025-04-07 09:40
Notice of Annual General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be...